Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

Abstract

Background: We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia. Methods: A total of 809 patients with essential thrombocythemia who were at high risk for vascular events received low-dose aspirin plus either anagrelide or hydroxyurea. The composite primary end point was the actuarial risk of arterial thrombosis (myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, or peripheral arterial thrombosis), venous thrombosis (deep-vein thrombosis, splanchnicvein thrombosis, or pulmonary embolism), serious hemorrhage, or death from thrombotic or hemorrhagic causes. Results: After a median follow-up ..